Emrusolmin is named as an intervention in 3 current clinical trials in our USA, Germany, France, Spain, Italy, Japan and Israel registers. 3 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Teva Branded Pharmaceutical Products R&D LLC. The most-studied condition is Multiple System Atrophy.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237 · ClinicalTrials.gov ↗ · Multiple System Atrophy
|
Phase 2 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | USA, Germany, France, Spain, Italy, Japan, Israel |
|
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT07197866 · ClinicalTrials.gov ↗ · Multiple System Atrophy
|
Phase 2 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | USA, Germany, France, Spain, Italy, Japan, Israel |
|
A Trial to Assess TEV-56286 at Different Doses in Healthy Participants
NCT07674940 · Healthy Volunteers
|
Phase 1 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Teva Branded Pharmaceutical Products R&D LLC | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 3 |
| Clinical trials in Germany | 2 | 2 |
| Clinical trials in France | 2 | 2 |
| Clinical trials in Spain | 2 | 2 |
| Clinical trials in Italy | 2 | 2 |
| Clinical trials in Japan | 2 | 2 |
| Clinical trials in Israel | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Germany, France, Spain, Italy, Japan and Israel registers name Emrusolmin (also registered as TEV-56286) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in USA, 2 with sites in Germany, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Japan and 2 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Teva Branded Pharmaceutical Products R&D LLC. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Emrusolmin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Emrusolmin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Emrusolmin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.